Stock Events

Stock Events

CalciMedica 

$2.17
23
-$0.03-1.36% 10:52 Today

Statistics

Day High
2.27
Day Low
2.12
52W High
33.7
52W Low
2
Volume
94,575
Avg. Volume
276,973
Mkt Cap
15.02M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-2.25
-1.4
-0.55
0.3
Expected EPS
-1.275
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-29.56MNet Income

Analyst Ratings

9.00Average Price Target
The highest estimate is 9.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CALC. It's not an investment recommendation.
Lucid Group
5
LCID
Tesla
4
TSLA
Apple
3
AAPL
Microsoft
3
MSFT

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap137.3B
Vertex Pharmaceuticals is involved in the development of small molecule drugs for serious diseases, including inflammatory conditions, which puts it in direct competition with CalciMedica's focus on treatments for acute pancreatitis and other inflammatory diseases.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences focuses on antiviral drugs for infections like HIV, hepatitis B, hepatitis C, and influenza, but its expansion into other therapeutic areas, including inflammatory and respiratory diseases, makes it a competitor.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie operates in areas including immunology and chronic inflammatory conditions, directly competing with CalciMedica's development of treatments for diseases with inflammatory components.
AMGEN
AMGN
Mkt Cap233.78B
Amgen focuses on human therapeutics, including treatments for inflammatory diseases, making it a competitor in the biopharmaceutical space targeting similar conditions as CalciMedica.
Regeneron Pharmaceuticals
REGN
Mkt Cap81.77B
Regeneron Pharmaceuticals specializes in medicines for serious conditions, with a significant focus on inflammatory diseases, positioning it as a competitor to CalciMedica.
Biogen
BIIB
Mkt Cap32.28B
Biogen focuses on developing therapies for neurological and neurodegenerative diseases, but its interest in expanding into other areas, including inflammatory diseases, makes it a potential competitor.
Novartis
NVS
Mkt Cap292.35B
Novartis is a global healthcare company that operates across various segments, including pharmaceuticals that target inflammatory diseases, making it a competitor in the same therapeutic area as CalciMedica.
Pfizer
PFE
Mkt Cap159.36B
Pfizer develops and produces medicines and vaccines for a wide range of medical disciplines, including inflammation and immunology, directly competing with CalciMedica's focus areas.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson, through its pharmaceutical segment, develops treatments for a broad range of health conditions, including inflammatory diseases, making it a competitor.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca operates in several key therapeutic areas, including respiratory, inflammation, and autoimmunity, positioning it as a competitor to CalciMedica in the inflammation segment.

About

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The company operates as one operating segment focused on developing and commercializing therapeutics in the U.S.
Show more...
CEO
A. Rachel Leheny
Employees
15
Country
United States
ISIN
US38942Q3011

Listings

XNAS
US
CALC
BOATS
BOATS
CALC.BOATS

0 Comments

Share your thoughts

FAQ

What is CalciMedica stock price today?▼
The current price of CALC is $2.17 USD — it has decreased by -1.36% in the past 24 hours. Watch CalciMedica stock price performance more closely on the chart.
What is CalciMedica stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange CalciMedica stocks are traded under the ticker CALC.
Is CalciMedica stock price growing?▼
CALC stock has fallen by -5.17% compared to the previous week, the month change is a -44.65% fall, over the last year CalciMedica has showed a -86.12% decrease.
What is CalciMedica market cap?▼
Today CalciMedica has the market capitalization of 15.02M
When is the next CalciMedica earnings date?▼
CalciMedica is going to release the next earnings report on November 18, 2026.
What were CalciMedica earnings last quarter?▼
CALC earnings for the last quarter are -2.25 USD per share, whereas the estimation was -1.43 USD resulting in a -57.89% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is CalciMedica revenue for the last year?▼
CalciMedica revenue for the last year amounts to 0 USD.
What is CalciMedica net income for the last year?▼
CALC net income for the last year is -29.56M USD.
How many employees does CalciMedica have?▼
As of September 04, 2026, the company has 15 employees.
In which sector is CalciMedica located?▼
CalciMedica operates in the Health & Wellness sector.
When did CalciMedica complete a stock split?▼
The last stock split for CalciMedica was on August 31, 2026 with a ratio of 1:5.
Where is CalciMedica headquartered?▼
CalciMedica is headquartered in LA JOLLA, United States.